false
0001551152
Common Stock, $0.01 Par Value
ABBV
0001551152
2024-02-14
2024-02-14
0001551152
us-gaap:CommonStockMember
exch:XNYS
2024-02-14
2024-02-14
0001551152
us-gaap:CommonStockMember
exch:XCHI
2024-02-14
2024-02-14
0001551152
abbv:SeniorNotes1.375Percentdue2024Member
exch:XNYS
2024-02-14
2024-02-14
0001551152
abbv:SeniorNotes1.250Percentdue2024Member
exch:XNYS
2024-02-14
2024-02-14
0001551152
abbv:SeniorNotes0.750Percentdue2027Member
exch:XNYS
2024-02-14
2024-02-14
0001551152
abbv:SeniorNotes2.125Percentdue2028Member
exch:XNYS
2024-02-14
2024-02-14
0001551152
abbv:SeniorNotes2.625Percentdue2028Member
exch:XNYS
2024-02-14
2024-02-14
0001551152
abbv:SeniorNotes2.125Percentdue2029Member
exch:XNYS
2024-02-14
2024-02-14
0001551152
abbv:SeniorNotes1.250Percentdue2031Member
exch:XNYS
2024-02-14
2024-02-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
February 14, 2024
ABBVIE INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-35565 |
|
32-0375147 |
(State or other jurisdiction of
incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer Identification No.) |
1 North Waukegan Road |
| |
North Chicago, Illinois |
| 60064-6400 |
(Address of principal executive offices) |
| (Zip Code) |
(847) 932-7900
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under
any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.01 Par Value |
|
ABBV |
|
New York Stock Exchange Chicago Stock Exchange |
1.375% Senior Notes due 2024 |
|
ABBV24 |
|
New York Stock Exchange |
1.250% Senior Notes due 2024 |
|
ABBV24B |
|
New York Stock Exchange |
0.750% Senior Notes due 2027 |
|
ABBV27 |
|
New York Stock Exchange |
2.125% Senior Notes due 2028 |
|
ABBV28 |
|
New York Stock Exchange |
2.625% Senior Notes due 2028 |
|
ABBV28B |
|
New York Stock Exchange |
2.125% Senior Notes due 2029 |
|
ABBV29 |
|
New York Stock Exchange |
1.250% Senior Notes due 2031 |
|
ABBV31 |
|
New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Common Stock, $0.01 Par Value |
ABBV |
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
On February 14, 2024, the Board of Directors (the “Board”)
of AbbVie Inc. (the “Company”) unanimously selected Robert A. Michael to succeed Richard A. Gonzalez as the Company’s
Chief Executive Officer (CEO). Mr. Gonzalez, who has served as CEO since the company’s formation in 2013, will retire from the role
of CEO and become Executive Chairman of the Board of Directors, effective July 1, 2024. The Board also appointed Mr. Michael as a member
of the Board of Directors as a Class II director, effective July 1, 2024.
Mr. Michael is currently AbbVie’s President and Chief Operating
Officer. Mr. Michael previously served as Vice Chairman and President from June 2022 to July 2023, as Vice Chairman, Finance and Commercial
Operations and Chief Financial Officer from June 2021 to June 2022, as Executive Vice President, Chief Financial Officer from 2019 to
2021, as Senior Vice President, Chief Financial Officer from 2018 to 2019 and as Vice President, Controller from 2017 to 2018. He served
as AbbVie’s Vice President, Treasurer from 2015 to 2016, as Vice President, Controller, Commercial Operations from 2013 to 2015
and as Vice President, Financial Planning and Analysis from 2012 to 2013. At Abbott, Mr. Michael served as Division Controller, Nutrition
Supply Chain from 2010 to 2012. Mr. Michael joined Abbott in 1993 and was first appointed as an AbbVie corporate officer in March 2017.
Mr. Michael will not receive any additional compensation for his service
on the Board.
Item 7.01 Regulation FD Disclosure.
On February 20, 2024, the Company issued a press release announcing
the appointment of Mr. Michael as Chief Executive Officer, effective July 1, 2024. A copy of the press release is furnished as Exhibit
99.1 to this Current Report on Form 8-K.
The information in this Item 7.01, including Exhibit 99.1 attached
hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated
by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange
Act, except as otherwise expressly stated in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
|
ABBVIE INC. |
|
|
|
|
By: |
/s/ Perry C. Siatis |
Date: February 20, 2024 |
Name: |
Perry C. Siatis |
|
Title: |
Executive Vice President, General Counsel and Secretary |
Exhibit 99.1
PRESS RELEASE
AbbVie Announces Appointment of Robert
A. Michael as Chief Executive Officer
| - | Richard
A. Gonzalez to retire as AbbVie CEO to become executive chairman |
| - | Transition
will occur on July 1, 2024 |
NORTH CHICAGO, Ill., February 20,
2024 -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously selected Robert A. Michael, AbbVie’s
current president and chief operating officer, to succeed Richard A. Gonzalez as the company’s chief executive officer (CEO). Mr.
Gonzalez, who has served as CEO since the company’s formation in 2013, will retire from the role of CEO and become executive chairman
of the board of directors, effective July 1, 2024. Additionally, the board has appointed Mr. Michael as a member of the board of directors
effective July 1, 2024.
“On behalf of AbbVie’s board,
I am extremely excited that Rob has agreed to serve as AbbVie’s next CEO,” said Richard A. Gonzalez, chairman and chief executive
officer, AbbVie. “As a key member of the Executive Leadership Team, he has had a tremendous impact on AbbVie. From establishing
our financial planning organization, to the development of our diversified business strategy, to successfully navigating the end of exclusivity
for Humira in the U.S., Rob has been integral to AbbVie’s impact since inception. Rob has also played an important role in key
business development opportunities that have been critical to delivering on our long-term growth strategy, including the acquisitions
of Allergan and ImmunoGen and the pending Cerevel Therapeutics transaction. I have known and worked with Rob for many years, and he has
the experience, leadership capabilities and strategic vision to accelerate AbbVie’s success well into the future.”
“The board and I have been planning
for a seamless CEO succession for some time. Now is the opportune time to hand the CEO role over to Rob,” continued Mr. Gonzalez.
“The business is performing very well and is in a strong position for the long term. Our pipeline contains multiple promising candidates
to sustain our future strong growth. It has been a privilege and immensely gratifying to serve with all my AbbVie colleagues for the
past 11 years growing AbbVie into what it is today, and I look forward to continuing to work with Rob as executive chairman of the board.”
“The AbbVie board recognizes that
CEO succession planning is one of our most important responsibilities,” said Glenn Tilton, lead independent director, AbbVie’s
board of directors. “The company has been planning for the eventual succession for a long time and has been thoughtful and deliberate
to ensure the right plan was in place for a potential successor. The board conducted a thorough process to identify the right leader
for AbbVie’s next chapter. It is a testament to the strength and depth of AbbVie’s management team that we have the ideal
internal candidate in Rob to assume the CEO position. The board has the highest confidence in Rob and looks forward to working with him
to create meaningful value for our shareholders and all our stakeholders.”
AbbVie Inc. |
+1 (847) 938-9190 |
1 North Waukegan Road |
abbvie.com |
North Chicago, IL 60064
“All of us at AbbVie owe Rick
an enormous debt of gratitude for his remarkable leadership over the past 11 years,” continued Mr. Tilton. “Under his stewardship,
AbbVie has generated a total return to shareholders of more than 700%, created over $250 billion in market valuation, grown our annual
patient base to more than 60 million people in 175 countries, invested over $60 billion in R&D and nearly tripled annual revenue.
We are thrilled that we will continue to benefit from Rick’s experience, intellect and integrity on AbbVie’s board of directors.”
“I am honored to assume the CEO
role for AbbVie, and I am excited about our company’s bright future,” said Robert A. Michael, president and chief operating
officer, AbbVie. “Rick has been a tremendous leader for AbbVie and mentor to me personally. His legacy at AbbVie will be felt for
years to come. I would like to thank the board for expressing its confidence in me, and I look forward to working with Rick and the entire
board to deliver results for our patients, our employees, our shareholders and our communities.”
About Robert A. Michael
Robert A. Michael is president and chief
operating officer of AbbVie. A member of AbbVie’s Executive Leadership Team, Mr. Michael is responsible for global commercial operations,
finance, corporate human resources, global operations, business development and corporate strategy for the company. Previously, he served
as vice chairman and president.
Mr. Michael has 31 years of experience
including leadership roles across multiple businesses, including pharmaceuticals, aesthetics, diagnostics, diabetes care and nutrition.
He began his career with Abbott as a member of the financial development program and ultimately served as division controller, nutrition
supply chain and division controller, molecular diagnostics, among other roles.
Upon AbbVie’s separation from
Abbott in 2013, Mr. Michael established and led the company’s first financial planning organization as vice president, AbbVie financial
planning and analysis. He then held a series of leadership roles of increasing responsibility including vice president, controller for
commercial operations; vice president, treasurer; and vice president, corporate controller. He was appointed chief financial officer
in 2018, vice chairman, finance and commercial operations in 2021, vice chairman and president in 2022 and president and chief operating
officer in 2023.
About Richard A. Gonzalez
Richard A. Gonzalez is chairman of the
board and CEO of AbbVie. Mr. Gonzalez is AbbVie’s founding CEO, having led the company since its inception in 2013. During his
tenure as CEO, AbbVie market capitalization has increased from $54 billion in 2013 to more than $300 billion today, revenue has nearly
tripled and adjusted, diluted EPS has grown from $2.93 to $11.11.1 In that time, AbbVie has grown to more than 50,000 employees
and serves patients in more than 175 countries with its portfolio of innovative medicines.
1 Reflects full-year non-GAAP
measure adjusted for specified items, including intangible asset amortization and impairment, change in fair value of contingent consideration
and other adjustments. 2013 diluted EPS was $2.56, and 2023 diluted EPS was $2.72.
AbbVie Inc. |
+1 (847) 938-9190 |
1 North Waukegan Road |
abbvie.com |
North Chicago, IL 60064
Prior to AbbVie’s separation from
Abbott in January 2013, Mr. Gonzalez was a 30-year Abbott veteran. He served as president and chief operating officer of Abbott. He also
held various senior leadership positions in Abbott’s Medical Products businesses, including president and chief operating officer
of the Medical Products Group; senior vice president and president of the former Hospital Products Division; vice president and president
of the Health Systems Division; and divisional vice president and general manager for Diagnostics Operations in the United States and
Canada.
Mr. Gonzalez has been a long-standing
leader in the greater Chicago community where he serves on the University of Chicago Board of Trustees and as a member of the Commercial
Club of Chicago.
About AbbVie
AbbVie's mission is to discover and
deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We
strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience
and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit
us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter) and YouTube.
AbbVie Forward-Looking Statements
Some statements in this news release
are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words
"believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional
verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such
risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties
inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable
to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect
AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2022 Annual Report on Form 10-K, which has been filed
with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation,
and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments,
except as required by law.
###
Media:
Jackie Pacelli
(224) 358-8128
jaquelin.pacelli@abbvie.com |
Investors:
Liz Shea
(847) 935-2211
liz.shea@abbvie.com |
AbbVie Inc. |
+1 (847) 938-9190 |
1 North Waukegan Road |
abbvie.com |
North Chicago, IL 60064
v3.24.0.1
Cover
|
Feb. 14, 2024 |
Document Information [Line Items] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Feb. 14, 2024
|
Entity File Number |
001-35565
|
Entity Registrant Name |
ABBVIE INC.
|
Entity Central Index Key |
0001551152
|
Entity Tax Identification Number |
32-0375147
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
1 North Waukegan Road
|
Entity Address, City or Town |
North Chicago
|
Entity Address, State or Province |
IL
|
Entity Address, Postal Zip Code |
60064-6400
|
City Area Code |
847
|
Local Phone Number |
932-7900
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
false
|
Common Stock [Member] | NEW YORK STOCK EXCHANGE, INC. [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
Common Stock, $0.01 Par Value
|
Trading Symbol |
ABBV
|
Security Exchange Name |
NYSE
|
Common Stock [Member] | NYSE CHICAGO, INC. [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
Common Stock, $0.01 Par Value
|
Trading Symbol |
ABBV
|
Security Exchange Name |
CHX
|
Senior Notes 1. 375 Percentdue 2024 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
1.375% Senior Notes due 2024
|
Trading Symbol |
ABBV24
|
Security Exchange Name |
NYSE
|
Senior Notes 1. 250 Percentdue 2024 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
1.250% Senior Notes due 2024
|
Trading Symbol |
ABBV24B
|
Security Exchange Name |
NYSE
|
Senior Notes 0. 750 Percentdue 2027 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
0.750% Senior Notes due 2027
|
Trading Symbol |
ABBV27
|
Security Exchange Name |
NYSE
|
Senior Notes 2. 125 Percentdue 2028 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
2.125% Senior Notes due 2028
|
Trading Symbol |
ABBV28
|
Security Exchange Name |
NYSE
|
Senior Notes 2. 625 Percentdue 2028 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
2.625% Senior Notes due 2028
|
Trading Symbol |
ABBV28B
|
Security Exchange Name |
NYSE
|
Senior Notes 2. 125 Percentdue 2029 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
2.125% Senior Notes due 2029
|
Trading Symbol |
ABBV29
|
Security Exchange Name |
NYSE
|
Senior Notes 1. 250 Percentdue 2031 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
1.250% Senior Notes due 2031
|
Trading Symbol |
ABBV31
|
Security Exchange Name |
NYSE
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_EntityListingsExchangeAxis=exch_XNYS |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_EntityListingsExchangeAxis=exch_XCHI |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes1.375Percentdue2024Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes1.250Percentdue2024Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes0.750Percentdue2027Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes2.125Percentdue2028Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes2.625Percentdue2028Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes2.125Percentdue2029Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes1.250Percentdue2031Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
AbbVie (NYSE:ABBV)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
Von Mai 2023 bis Mai 2024